Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Malta.
Press releases published on September 15, 2025
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAs Large …
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), …
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,000 Short Bowel Syndrome (SBS) …
Berry Street Launches GLP-1 Nutrition Pathway Program
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Berry Street, an AI-powered nutrition therapy platform, today announced the launch of its GLP-1 Nutrition Pathway Program, a comprehensive, structured program designed to promote preventative health, and improve …
Conceivable Life Sciences asegura $50 millones de dólares en ronda de financiación Serie A
La startup de biotecnología lidera desde México la revolución en medicina reproductiva con AURA, el primer laboratorio de Fecundación In Vitro (FIV) automatizado y potenciado por inteligencia artificial (IA) Con esta inversión, Conceivable se convierte en …
Conceivable Life Sciences Secures $50 Million Series A
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Conceivable Life Sciences today announced its $50 million Series A financing to accelerate the development and commercialization of the world's first AI-powered automated IVF laboratory. The funding will support …
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy Study addresses lack of awareness and real-world data with oral film formulation of clobazam …
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the …
More than 3.7 Million Teens Participate in Planet Fitness' High School Summer Pass™ Program, Building Lifelong Health and Wellness Habits Through Fitness
TORONTO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Planet Fitness, one of the largest and fastest-growing franchisors and operators of fitness centers with more members than any other fitness brand, announced record-breaking participation in its 2025 High School …
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces the successful conduct of its scheduled Type C meeting (written response) on Alzheimer’s disease (AD) with the US Food …
KFSHRC Reduces Emergency Department Inpatient Bed Waiting Time by 75%
RIYADH, Saudi Arabia, Sept. 15, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has reduced the median emergency department boarding time from over 13 hours in 2023 to just 3.2 hours by mid 2025, achieving a …
Request for Secretary of State of Texas, Jane Nelson, to Organize a Public Meeting Between Crosetto and CPRIT Scientists Who Have Allocated $3.65 Billion of $6 Billion to Cancer Research
DALLAS, Sept. 15, 2025 (GLOBE NEWSWIRE) -- (In PDF https://bit.ly/3VPIFvY) The Crosetto Foundation for the Reduction of Cancer Deaths, a registered nonprofit with North Texas Giving Day (https://www.northtexasgivingday.org/organization/1951), has earned …
Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development …
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
CAMBRIDGE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced a poster …
ABLi Therapeutics to Present “Clinical Breakthrough Lecture” at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
ATLANTA and BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results …
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight …
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food …
Heroes on the Water Receives $15,000 Sponsorship from Cigna to Support BAMC Therapeutic Program
Allen, Texas, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Heroes on the Water (HOW) received a $15,000 sponsorship from Cigna Healthcare in support of its Brooke Army Medical Center (BAMC) Therapeutic Program in San Antonio, Texas. This program provides active-duty …
Picard Medical Reports Second Quarter 2025 Financial Results
Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American …